Tuesday, October 4, 2022


Biotechnology News Magazine

Medsenic Announces Positive Results of its Phase II Clinical Study with Arscimed® for the Rx of Chronic Graft Versus Host Disease

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 29, 2021

Medsenic announced today the positive results of its Phase II clinical study “GMED-16-001” with its lead product Arscimed®, an intravenous formulation of arsenic trioxide, in patients with Chronic Graft Versus Host Disease (GvHD).

“These excellent results are a significant step forward for the management of patients with cGvHD, a rare, complex and extremely debilitating autoimmune disease affecting over 40,000 people worldwide and for which there is no satisfactory treatment. The study data validate the therapeutic potential of our product Arscimed®, as a new selective immunosuppressive/anti-inflammatory drug for cGvHD. We look forward to confirming its efficacy in a Phase III study as well as its significant impact on improving the quality of life of GvHD patients,” said Prof. François Rieger, President, and co-founder of Medsenic.

The primary endpoint of this prospective Phase II multicentre, non-randomised study was the improvement of treatment response, i.e., complete or partial disease remission 6 months after GvHD diagnosis, with Arscimed® in combination with prednisone with or without cyclosporine.

Over a 4-week period, 21 patients with moderate to severe chronic GvHD received as first-line treatment daily intravenous infusions of Medsenic’s arsenic trioxide drug. The first improvements were observed 6 weeks after the first infusion. The reduction of the initial dose of 1 mg prednisone/kg/day (standard care with or without cyclosporine) can be started at this stage, with a view to discontinue corticosteroids once complete remission has been achieved. This ability to eliminate the use of corticosteroids is a major advantage of arsenic trioxide treatment.

After the 6-month follow-up, the study’s primary endpoint was met in 15 of 21 patients, with a 75% clinical efficacy rate (95% exact CI: [50.9%; 91.3%]). This very encouraging result was confirmed by a sustained response at 12 months post-treatment in all patients.

About Arscimed®

The active pharmaceutical ingredient (API) of Arscimed® is arsenic trioxide. Medsenic has harnessed its expertise to develop and manufacture a formulation of arsenic trioxide for IV injection. Arsenic trioxide belongs to a new class of drugs able to radically modify the autoimmune cascade and normalize the immune system without causing nonspecific immunosuppression.

The main action of arsenic trioxide is the activation of a strong oxidative stress-induced pathway in activated immune cells, and the elimination of certain subtypes of pathogenic immune cells eliciting autoimmune reactions. It also suppresses abnormal biological processes associated with immune disorders, such as the excessive production of proinflammatory cytokine.

About cGvHD

cGvHD – Chronic Graft versus Host Disease – is a complex autoimmune reaction that develops following bone marrow transplants or, more precisely, allogeneic hematopoietic stem cells, with a frequency of 30-60 % of the treated patients. It affects each year approximately 16,000 people in the European Union and 20,000 in the United States and Canada, which places it under the classification of Orphan Disease.

After grafting, the donor immunocompetent cells often trigger an immune response against the recipient – called the “Host”. They will recognize the recipient’s own antigens as foreign and will seek to destroy them. The donor’s T cells thus attack the host’s tissues and organs. This phenomenon can even be observed between donor and host who are very close immunologically. This disease remains a major obstacle to therapeutic transplants in hemato-oncology… A so-called acute GvHD occurs in the weeks following transplantation. After a certain period of time, the reaction changes in nature and displays autoimmune disease characteristics. It becomes chronic, with a continuous aggravation, often uncontrolled by conventional immunosuppressive treatments, and has a poor prognosis, making cGvHD potentially fatal. This is why there is an urgent need for new therapeutic approaches.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine